A. Menarini
Privately held: no public share price
Assets
(8 total)
8Total Assets
3Approved
5Phase 3 / Filed
0Phase 1–2 / Early
10Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Estrogen receptorSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | 5-HT1B/1D receptorSmall molecule | Migraine | |
| Approved | XPO1 (exportin-1)Small molecule | Multiple MyelomaMyelofibrosisEndometrial Cancer | |
| Phase 3 | GLP-1 receptorPeptide | ObesityType 2 Diabetes | |
| Phase 3 | α2δ-1 subunit of voltage-gated calcium channelsSmall molecule | Diabetic Peripheral Neuropathic Pain | |
| Phase 3 | CETPSmall molecule | Type 2 DiabetesAtherosclerotic Cardiovascular DiseaseAlzheimer's Disease Early Alzheimer's Disease | |
| Phase 3 | CETP · NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease | |
| Phase 3 | Cardiac late sodium current (late INa, Nav1.5)Small molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (5)
November 2026 (3)
2027 (5)
April 2027 (1)
June 2027 (2)
August 2027 (1)
ElacestrantPhase 1/2Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases …
Est. primary completion 2027-08 · NCT05386108 · CT.gov ↗
What to watch
November 2027 (1)
Est. primary completion 2027-11-14 · NCT07493057 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
March 2028 (1)
Est. primary completion 2028-03 · NCT07219602 · CT.gov ↗
What to watch
September 2028 (2)
October 2028 (1)
Est. primary completion 2028-10 · NCT07766018 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Est. primary completion 2029-08 · NCT06492616 · CT.gov ↗
What to watch
Regulatory and conference events
(16)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
17 November 2026Filing acceptedSelinexorFDA accepts the XPOVIO plus ruxolitinib sNDA in myelofibrosis
US, FDA · Source ↗
EU, EC · NewAmsterdam Pharma and Menarini Group · Source ↗
EU, EC · NewAmsterdam Pharma and Menarini Group · Source ↗
3 September 2026Licensing dealGZR18 (bofanglutide)Gan & Lee licenses bofanglutide to Menarini for Europe (39 countries)
Gan & Lee Pharmaceuticals; The Menarini Group · Source ↗
31 August 2026Filing submittedSelinexor (Xpovio)Karyopharm submits an sNDA to FDA for XPOVIO plus ruxolitinib in myelofibrosis (accelerated approval, Priority Review requested)
US, FDA · Karyopharm Therapeutics Inc. · Source ↗
30 July 2026Topline resultSelinexor (Xpovio)Phase 3 XPORT-EC-042 (NCT05611931) of selinexor maintenance in endometrial cancer did not meet its PFS primary endpoint
Global · Karyopharm Therapeutics Inc. · Source ↗
Gan & Lee Pharmaceuticals · Source ↗
24 March 2026Topline resultSelinexor (Xpovio)Phase 3 SENTRY (NCT04562389) met its first co-primary endpoint (SVR35) and missed its second (Abs-TSS)
Global · Karyopharm Therapeutics Inc. · Source ↗
March 2026WithdrawalSelinexorAccelerated approval in DLBCL voluntarily withdrawn at the FDA's request
US, FDA · Source ↗
16 December 2025ApprovalSelinexorMalaysia approves XPOVIO (selinexor) sNDA for relapsed/refractory DLBCL
MY, NPRA · Source ↗
EU, EMA · Source ↗
The 12 most recent of 15 past events are shown.
Financial reports
No financial reports recorded.